Aquisition: Cardiogeni Plc
Cardiogeni Plc (Cardiogeni), a UK clinical stage biotechnology company developing heart failure medicines, is pleased to announce its admission of its entire share capital to trading on the Access segment of the Aquis Stock Exchange.
Cardiogeni ’s strategy is to build a range of products in cardiac regeneration. Cardiogeni’s lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery. CLXR-001 has received regulatory approval to begin a randomised controlled trial from the national regulatory authority of a European Union member country and this trial has begun dosing patients with interim data expected to be read-out within 18 months of admission.
In addition, Cardiogeni has two follow-on products (CLXR-002 and CLX-003) target the larger cardiac market segments of stent treatment and myocardial infarction (heart attacks). Each of the products has the potential to become a first or best-in-class medicine.
Crowe's Role and Team
Crowe acted as reporting accountant on the transaction. Our Capital Markets team was led by Paul Blythe, supported by James Leyton and Monty Cann.
Client quote
"We were very pleased with the support we received from the team at Crowe. Their experience in the capital markets process was clearly demonstrated during the admission process. This transaction marks an important step for Cardiogeni Plc and provides an excellent platform for the development of our portfolio."
Darren Disley, Executive Chairman, Cardiogeni Plc
